NX-5948 NEW
| Price | $378 | $838 | $1330 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-10 |
Product Details
| Product Name: NX-5948 | CAS No.: 2649400-34-8 |
| Purity: 98.29% | Supply Ability: 10g |
| Release date: 2025/11/10 |
Product Introduction
Bioactivity
| Name | NX-5948 |
| Description | NX-5948 (BTK-IN-24) is an orally bioavailable and blood-brain barrier-penetrable PROTAC BTK degrader with anti-inflammatory and antitumor activities. It induces BTK protein degradation via the cereblon E3 ligase complex, inhibiting B cell activation. |
| In vitro | NX-5948 (0.0001-1000 nM; 4 hrs) is a potent degrader of BTK in primary human B cells (DC50=0.34 nM) and inhibits BCR signaling. In Ramos cells, NX-5948 (10 nM; 0.25, 0.5, 1, 2, 4, 6, 18, 24 hr) rapidly catalyzes BTK degradation within 1 hr and completes the degradation process within 2 hr. [1] NX-5948 induces BTK degradation in lymphoma cell lines and PBMC (DC50< 1 nM). [3] |
| In vivo | In a mouse model of collagen-induced arthritis (CIA), NX-5948 (10, 30 mg/kg; oral gavage; daily; days 18-36) demonstrated good efficacy and tolerability, inhibiting antibody titers and cytokine IL-6 levels. [1] NX-5948 (3, 10, 30 mg/kg; oral gavage) caused dose- and time-dependent decreases in circulating BTK levels in mice and non-human primate and cynomolgus monkeys. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 40 mg/mL (49.57 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) |
| Inhibitors Related | evobrutinib | (±)-Zanubrutinib | ARV-471 | Sunvozertinib | dBET6 | Ibrutinib | IBT6A | Dbet57 | Orelabrutinib | ARV-825 | AU-15330 | Tyrosinase-IN-16 |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | CNS-Penetrant Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $105.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-11-09 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY